L

Lytix Biopharma AS
F:6BG

Watchlist Manager
Lytix Biopharma AS
F:6BG
Watchlist
Price: 0.778 EUR -0.51%
Market Cap: 473.5k EUR

Intrinsic Value

6BG price has not been updated for more than 4 years. This may indicate that the stock has been delisted.

The intrinsic value of one 6BG stock under the Base Case scenario is 0.006 EUR. Compared to the current market price of 0.778 EUR, Lytix Biopharma AS is Overvalued by 99%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

6BG Intrinsic Value
0.006 EUR
Overvaluation 99%
Intrinsic Value
Price
L
Worst Case
Base Case
Best Case

Valuation History
Lytix Biopharma AS

What is Valuation History?
Ask AI Assistant
What other research platforms think about 6BG?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is 6BG valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Lytix Biopharma AS.

Explain Valuation
Compare 6BG to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about LYTIX?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Lytix Biopharma AS

Current Assets 107.5m
Cash & Short-Term Investments 60.1m
Receivables 7.3m
Other Current Assets 40.2m
Non-Current Assets 2.6m
PP&E 2.6m
Current Liabilities 18.4m
Accounts Payable 2.7m
Other Current Liabilities 15.7m
Non-Current Liabilities 1.7m
Long-Term Debt 1.7m
Efficiency

Free Cash Flow Analysis
Lytix Biopharma AS

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Lytix Biopharma AS

Revenue
608k NOK
Operating Expenses
-74.8m NOK
Operating Income
-74.2m NOK
Other Expenses
1.3m NOK
Net Income
-72.9m NOK
Fundamental Scores

6BG Profitability Score
Profitability Due Diligence

Lytix Biopharma AS's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

17/100
Profitability
Score

Lytix Biopharma AS's profitability score is 17/100. The higher the profitability score, the more profitable the company is.

6BG Solvency Score
Solvency Due Diligence

Lytix Biopharma AS's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Lytix Biopharma AS's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

6BG Price Targets Summary
Lytix Biopharma AS

Wall Street analysts forecast 6BG stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 6BG is 1.093 EUR with a low forecast of 1.082 EUR and a high forecast of 1.125 EUR.

Lowest
Price Target
1.082 EUR
39% Upside
Average
Price Target
1.093 EUR
40% Upside
Highest
Price Target
1.125 EUR
45% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Lytix Biopharma AS
does not pay dividends
Shareholder Yield

Current shareholder yield for LYTIX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one 6BG stock?

The intrinsic value of one 6BG stock under the Base Case scenario is 0.006 EUR.

Is 6BG stock undervalued or overvalued?

Compared to the current market price of 0.778 EUR, Lytix Biopharma AS is Overvalued by 99%.

Back to Top